Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin

Gonadotropin releasing hormone (GnRH) agonists have shown to be effective in the treatment of several sex-hormone-dependent conditions. However, their use could be limited by the bone loss they induce. To evaluate the use of nasal salmon calcitonin (sCT) in preventing this bone loss, 40 patients with endometriosis were treated for 6 months with triptoreline (3.75 mg monthly) and calcium (1 g daily), and randomized in three groups — placebo, sCT 100 IU daily and sCT 200 IU daily — in a prospective double-masked study. Dual-energy X-ray absorptiometry and biochemical parameters were used to evaluate the benefit of the treatment. At baseline, there were no statistically significant differences between the groups. After 6 months, estradiol and biochemical markers of bone metabolism were at postmenopausal levels, with no difference between the groups. There was no difference in bone loss in the three groups, at all sites. Mean lumbar bone loss was 4.01±2.59% (mean±SD) in this population. In this study dosages of 100 IU and 200 IU daily of nasal sCT were insufficient to prevent bone loss during GnRH agonist treatment. Similar content being viewed by others

Sandow J. Clinical applications of LHRH and its analogues. Clin Endocrinol 1983;18:571–86. Shaw RW. Treatment of endometriosis. Lancet 1992;340:1267–71. Gudmundsson JA, Ljunghall S, Bergquist C, Wide L, Nillius SJ. Increased bone turnover during gonadotropin-releasing hormone superagonist induced ovulation inhibition. J Clin Endocrinol Metab 1987;65:159–63. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C. The effect of a gonadrotropin-releasing hormone agonist analog (Nafarelin) on bone metabolism. J Clin Endocrinol Metab 1987;67:701–6. Matta WH, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol 1988;29:45–51. Bianchi G, Costantini S, Anserini P, et al. Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density. Maturitas 1989;11:179–85. Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989;52:21–6. Scharla SH, Minne HW, Waibel-Treber S, et al. Bone mass reduction after estrogen deprivation by long-acting ganadotrophin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1990;70:1055–61. Devogelaer JP, Nagant de Deuxchaisnes C, Donnez J. Action of the luteinizing hormone releasing hormone agonists on bone mineral density. In: Brosens I, Donnez J, editors. The current status of endometriosis: research and management. Proceedings of the 3rd World Congress on Endometriosis, Brussels, June 1992. New York: Parthenon Publishing, 1993:345–68. Devogelaer JP, Nagant de Deuxchaines C, Clerckx F, Donnez J. Effect of goserelin implants, an LHRH analogue, on lumbar and hip BMD, as studied by the DEXA technique. Calcif Tissue Int 1991;48(Suppl):298. Cann CE, Henzl M, Burry K et al. Reversible bone loss is produced by the GnRH agonist nafarelin. In: Cohn DV, Martin TJ, Meunier PJ, editors. Calcium regulation and bone metabolism: basic and clinical aspects, vol 9. Amsterdam: Excerpta Medica, 1987:123–7. Whitehouse RW, Adams JE, Baucroff K, Vaughan-Williams CA, Elstein M. The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clin Endocrinol 1990;33:365–73. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990; 70:920–24. Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and longacting gonadotropin releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992;75:558–63. Friedman AJ, Daly M, Juneau-Norcross M, et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin ‘add-back’ regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993;76:1439–45. Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Franchimont P. One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Miner Res 1988;3:249–52. Reginster JY, Denis D, Albert A, et al. One year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;2:1481–3. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ 1992;305:61. Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985;3:155–7. Roux C, Listrat V, Fechtenbaum J, et al. Bone mineral density of the proximal femur measured by dual energy X-ray absorptiometry. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Third International Symposium on Osteoporosis. Copenhagen: Osteopress, 1990:906–8. Roux C, Listrat V, Poiraudeau S, Dougados M, Amor B. Measurement of the bone density of the wrist by dual energy X-ray absorptiometry. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Third International Symposium on Osteoporosis. Copenhagen: Osteopress, 1990:903–5. Comite F, Delman M, Hutchinson-Williams K, Decherney AH, Jensen P. Reduced bone mass in reproductive aged women with endometriosis. J Clin Endocrinol Metab 1989;69:837–42. Lane N, Baptista J, Snow-Harter C. Bone mineral density of the lumbar spine in endometriosis subjects compared to an age similar control population. J Clin Endocrinol Metab 1991;72:510–4. Valente M, Primiero FM, Galoppi P, et al. Salmon calcitonin and bone turnover under GnRH analogue treatment. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Third International Symposium on Osteoporosis. Copenhagen: Osteopress, 1990;1426–9. Devogelaer JP, Nagant de Deuxchaisnes C, Lecart C, Donnez J, Thomas K. Inefficacy of the 50 units nasal spray of salmon calcitonin in patients after oophorectomy. J Bone Miner Res 1988;3(Suppl. 1):S162. Mazzuoli GF, Tabolli S, Bigi F, et al. Effects of salmon calcitonin on the bone loss induced by ovariectomy Calcif Tissue Int 1990;47:209–14. Ribot C, Tremollieres F, Pouilles JM, Chaumet-Riffaud P. Long term effect of nasal calcitonin on vertebral and femoral bone mass in early menopause: results of a controlled prospective 3-year study. J Bone Miner Res 1992; 7 (Suppl 1):415. Pouilles JM, Tremollières F, Ribot C. The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int 1993;52:340–3. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of trandermal 17β-estradiol on osteoporotic changes after surgical menopause: a two year placebo controlled trial. Am J Obstet Gynecol 1993;168:114–21. Bickerstaff DR, Kanis JA. The use of nasal cacitonin in the treatment of post-traumatic algodystrophy. Br J Rheum 1991;30:291–4. Dawood MY. Impact of medical treatment of endometriosis on bone mass. Am J Obstet Gynecol 1993;168:674–84. Rico H, Arnanz F, Revilla M, et al. Total and regional bone mineral content in women treated with GnRH agonists. Calcif Tissue Int 1993;52:354–7. Pascual E, Giner V, Arostegui A, Conill J, Ruiz MT, Pico A. Higher incidence of carpal tunnel syndrome in oophorectomized women. Br J Rheum 1991;31:60–2. Friedman AJ, Juneau-Norcross M, Rein MS. Adverse effects of leuprolide acetate depot treatment. Fertil Steril 1993;59:448–50. Chander CL, Spector TD. Oestrogens, joint disease, and cartilage. Ann Rheum Dis 1991;50:139–40. Author information Authors and Affiliations Rights and permissions About this article Cite this article Roux, C., Pelissier, C., Listrat, V. et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis Int 5, 185–190 (1995). https://doi.org/10.1007/BF02106098 Received: Accepted: Issue date: DOI: https://doi.org/10.1007/BF02106098